Pregled bibliografske jedinice broj: 890700
Repeated AAV-mediated gene transfer by serotype switching enables long-lasting therapeutic levels of hUgt1a1 enzyme in a mouse model of Crigler–Najjar Syndrome Type I
Repeated AAV-mediated gene transfer by serotype switching enables long-lasting therapeutic levels of hUgt1a1 enzyme in a mouse model of Crigler–Najjar Syndrome Type I // Gene therapy, 24 (2017), 649-660 doi:10.1038/gt.2017.75 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 890700 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Repeated AAV-mediated gene transfer by serotype switching enables long-lasting therapeutic levels of hUgt1a1 enzyme in a mouse model of Crigler–Najjar Syndrome Type I
Autori
Bočkor, Luka ; Bortolussi, Giulia ; Iaconcig, Alessandra ; Chiaruttini, Giulia ; Tiribelli, , Claudio ; Giacca Mauro ; Benvenuti, Federica Zentillin, Lorena ; Muro, Andrés F.
Izvornik
Gene therapy (0969-7128) 24
(2017);
649-660
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
AAV-mediated gene therapy, liver, Crigler-Najjar Type I, Ugt1a1, mouse models
Sažetak
Adeno-associated virus (AAV) -mediated gene therapy is a promising strategy to treat liver- based monogenic diseases. However, two major obstacles limit its success: first, vector dilution in actively dividing cells, such as hepatocytes in neonates/children, due to the non-integrating nature of the vector ; second, development of an immune response against the transgene and/or viral vector. Crigler–Najjar Syndrome Type I is a rare monogenic disease with neonatal onset, caused by mutations in the liver-specific UGT1 gene, with toxic accumulation of unconjugated bilirubin in plasma, tissues and brain. To establish an effective and long lasting cure, we applied AAV-mediated liver gene therapy to a relevant mouse model of the disease. Repeated gene transfer to adults by AAV-serotype switching, upon neonatal administration, resulted in lifelong correction of total bilirubin (TB) levels in both genders. In contrast, vector loss over time was observed after a single neonatal administration. Adult administration resulted in lifelong TB levels correction in male, but not female Ugt1−/− mice. Our findings demonstrate that neonatal AAV-mediated gene transfer to the liver supports a second transfer of the therapeutic vector, by preventing the induction of an immune response and supporting the possibility to improve AAV- therapeutic efficacy by repeated administration.
Izvorni jezik
Engleski
Znanstvena područja
Biologija, Kliničke medicinske znanosti, Biotehnologija
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE